The measured CSF/plasma donepezil concentration ratio but not individually measured CSF and plasma concentrations significantly increase over 24 h after donepezil treatment in patients with Alzheimer’s disease
Background: The acetylcholinesterase inhibitor donepezil is administered as a treatment for Alzheimer's disease (AD). However, the appropriate donepezil dosage is still a matter of debate. Methods: Forty AD patients receiving 10 mg/day of donepezil were randomly divided into four groups based o...
Main Authors: | Martin Valis, Alzbeta Dlabkova, Jakub Hort, Francesco Angelucci, Jaroslav Pejchal, Kamil Kuca, Zbysek Pavelek, Jana Zdarova Karasova, Michal Novotny |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-03-01
|
Series: | Biomedicine & Pharmacotherapy |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332223000112 |
Similar Items
-
Corrigendum to “The measured CSF/plasma donepezil concentration ratio but not individually measured CSF and plasma concentrations significantly increase over 24 h after donepezil treatment in patients with Alzheimer’s disease” [Biomed. Pharmacother. 159 (2023) 114223]
by: Martin Valis, et al.
Published: (2023-09-01) -
Impact of Plasma Donepezil Concentration on Behavioral and Psychological Symptoms of Dementia in Patients with Alzheimer’s Disease
by: Yoshiyuki Kagawa, et al.
Published: (2021-12-01) -
Effects of Concentration, Temperature and Polymer Type on Drug Release from Montmorillonite-Donepezil Nanocomposites
by: Naser Tavakoli, et al.
Published: (2013-04-01) -
Clinical Assessment of Alzheimer’s Disease and Response to Donepezil Treatment
by: Serge Gauthier
Published: (2020-12-01) -
Donepezil structure-based hybrids as potential multifunctional anti-Alzheimer’s drug candidates
by: Luca Piemontese, et al.
Published: (2018-01-01)